These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 18614389)

  • 1. Chemically modified siRNA: tools and applications.
    Watts JK; Deleavey GF; Damha MJ
    Drug Discov Today; 2008 Oct; 13(19-20):842-55. PubMed ID: 18614389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical modification of siRNA.
    Chernolovskaya EL; Zenkova MA
    Curr Opin Mol Ther; 2010 Apr; 12(2):158-67. PubMed ID: 20373259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical modification of small interfering RNA.
    Bramsen JB; Kjems J
    Methods Mol Biol; 2011; 721():77-103. PubMed ID: 21431680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. siRNA conjugate delivery systems.
    Jeong JH; Mok H; Oh YK; Park TG
    Bioconjug Chem; 2009 Jan; 20(1):5-14. PubMed ID: 19053311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of active small interfering RNAs.
    Peek AS; Behlke MA
    Curr Opin Mol Ther; 2007 Apr; 9(2):110-8. PubMed ID: 17458163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of small interfering RNAs modified by unlocked nucleic acid (UNA) to inhibit the heart-pathogenic coxsackievirus B3.
    Werk D; Wengel J; Wengel SL; Grunert HP; Zeichhardt H; Kurreck J
    FEBS Lett; 2010 Feb; 584(3):591-8. PubMed ID: 20005874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.
    Li SD; Huang L
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1317-23. PubMed ID: 19037838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3' terminal nucleotides determine thermodynamic stabilities of mismatches at the ends of RNA helices.
    Clanton-Arrowood K; McGurk J; Schroeder SJ
    Biochemistry; 2008 Dec; 47(50):13418-27. PubMed ID: 19053257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of chemically modified siRNA: Recent trends.
    Selvam C; Mutisya D; Prakash S; Ranganna K; Thilagavathi R
    Chem Biol Drug Des; 2017 Nov; 90(5):665-678. PubMed ID: 28378934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunostimulatory properties and antiviral activity of modified HBV-specific siRNAs.
    Shin D; Kim SI; Park M; Kim M
    Biochem Biophys Res Commun; 2007 Dec; 364(3):436-42. PubMed ID: 17963721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of gene silencing potency and nuclease stability by chemically modified duplex RNA.
    Kubo T; Zhelev Z; Bakalova R; Ohba H
    Nucleic Acids Symp Ser (Oxf); 2007; (51):407-8. PubMed ID: 18029759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine.
    Alshamsan A; Haddadi A; Incani V; Samuel J; Lavasanifar A; Uludağ H
    Mol Pharm; 2009; 6(1):121-33. PubMed ID: 19053537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent progress in chemically modified siRNAs.
    Gaglione M; Messere A
    Mini Rev Med Chem; 2010 Jun; 10(7):578-95. PubMed ID: 20500149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivering silence: advancements in developing siRNA therapeutics.
    Novobrantseva TI; Akinc A; Borodovsky A; de Fougerolles A
    Curr Opin Drug Discov Devel; 2008 Mar; 11(2):217-24. PubMed ID: 18283609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ analysis of single-stranded and duplex siRNA integrity in living cells.
    Raemdonck K; Remaut K; Lucas B; Sanders NN; Demeester J; De Smedt SC
    Biochemistry; 2006 Sep; 45(35):10614-23. PubMed ID: 16939213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
    Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
    Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems.
    Reischl D; Zimmer A
    Nanomedicine; 2009 Mar; 5(1):8-20. PubMed ID: 18640078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. siRNA vs. shRNA: similarities and differences.
    Rao DD; Vorhies JS; Senzer N; Nemunaitis J
    Adv Drug Deliv Rev; 2009 Jul; 61(9):746-59. PubMed ID: 19389436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sugar boost: when ribose modifications improve oligonucleotide performance.
    Faria M; Ulrich H
    Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.